X4 Pharmaceuticals, Inc. XFOR
Set alert
At close · Oct 30
After hours · Oct 30, 4:33 PM ET
- YTD
- -16.25%
- 1 year
- -16.04%
- Open
- 3.33
- Prev close
- 3.36
- Mkt cap
- 332.14M
- Vol
- 706.24K
- Avg vol
- 858.69K
- EPS
- 0.02
- P/E
- 167.50
- Div yield
- 0.00%
More statistics
- Low
- 3.19
- High
- 3.41
- Forward P/E
- -1.23
- Beta
- 0.39
- Short ratio
- 8.64
- Inst. own
- 67.66%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 8, 2024
- 50-d avg
- 0.50158
- 200-d avg
- 0.79766
- 1y target
- 3.05
News
3 days ago seekingalpha.com
X4 Pharmaceuticals, Inc. (XFOR) Analyst/Investor Day Transcript
X4 Pharmaceuticals, Inc. (XFOR) Analyst/Investor Day Transcript
3 days ago globenewswire.com
X4 Pharmaceuticals Highlights Clinical Progress and Market Opportunity for Mavorixafor in Primary Chronic Neutropenia During Virtual Investor Day
- Base Case U.S. Market Opportunity Estimated at 15,000 Patients, With Potential to Expand to Approximately 30,000 Patients -
3 days ago marketbeat.com
X4 Pharmaceuticals Targets 2028 Phase III Data for Mavorixafor in Chronic Neutropenia
X4 Pharmaceuticals NASDAQ: XFOR said it expects to complete enrollment in its pivotal Phase III 4WARD trial of mavorixafor for primary chronic neutropenia, or PCN, by the end of the fourth quarter of…
1 week ago defenseworld.net
Head to Head Review: Entrada Therapeutics (NASDAQ:TRDA) versus X4 Pharmaceuticals (NASDAQ:XFOR)
Entrada Therapeutics (NASDAQ: TRDA - Get Free Report) and X4 Pharmaceuticals (NASDAQ: XFOR - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will…
3 weeks ago globenewswire.com
X4 Pharmaceuticals to Host Virtual Investor Day on Thursday, October 29, 2026, Featuring Key Opinion Leaders
X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that the Company will host a virtual Investor Day on Thursday,…
3 weeks ago globenewswire.com
X4 Pharmaceuticals Secures Up to $150 Million Senior Debt Facility with K2 HealthVentures
- Repayment of Existing Loan Facility Completed - - Strengthens Financial Flexibility with Access to Funding for Corporate and Commercial Activities - - Expect Completion of Enrollment in Phase 3…
3 weeks ago defenseworld.net
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Stock Rated “Moderate Buy” by Sell-Side Brokerages
Shares of X4 Pharmaceuticals, Inc. (NASDAQ: XFOR - Get Free Report) have been given an average recommendation of "Moderate Buy" by the six brokerages that are covering the company, MarketBeat Ratings…
1 month ago globenewswire.com
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Oct. 01, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that, effective on…
1 month ago zacks.com
Down 25.4% in 4 Weeks, Here's Why X4 Pharmaceuticals (XFOR) Looks Ripe for a Turnaround
X4 Pharmaceuticals (XFOR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts…
1 month ago defenseworld.net
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Receives $11.25 Consensus Price Target from Brokerages
Shares of X4 Pharmaceuticals, Inc. (NASDAQ: XFOR - Get Free Report) have been given an average recommendation of "Moderate Buy" by the six brokerages that are currently covering the stock,…
1 month ago zacks.com
X4 Pharmaceuticals (XFOR) Loses 20.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
X4 Pharmaceuticals (XFOR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings…
1 month ago globenewswire.com
X4 Pharmaceuticals to Participate in a Fireside Chat at the 2026 Wells Fargo Healthcare Conference
BOSTON, Sept. 09, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that management will…
1 month ago globenewswire.com
X4 Pharmaceuticals Announces Positive Outcome from FDA Type C Meeting
- FDA Agrees to Reduced Sample Size for the Global 4WARD Phase 3 Chronic Neutropenia Trial - - Expect Completion of Enrollment by Year-End 2026 and Topline Data in H1 2028 - BOSTON, Sept. 08, 2026…
2 months ago globenewswire.com
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that, effective on…
2 months ago zacks.com
X4 Pharmaceuticals (XFOR) Upgraded to Buy: Here's Why
X4 Pharmaceuticals (XFOR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
2 months ago benzinga.com
Airsculpt Technologies, Barrick Mining And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
Summary: U.S. stock futures mixed, Dow futures down 0.1%. AirSculpt Technologies shares fell 13.4% after reporting Q2 results in-line with estimates. Other stocks moving lower in pre-market trading…
-
2 months ago benzinga.com
X4 Pharmaceuticals Q2 EPS $(0.13) Beats $(0.18) Estimate, Sales $8.806M Beat $2.420M Estimate
X4 Pharmaceuticals (NASDAQ:XFOR) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.18) by 27.78 percent. This is a 96.25 percent increase over losses of…
2 months ago globenewswire.com
X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update
BOSTON, Aug. 06, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today reported financial results for the…
3 months ago globenewswire.com
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that, effective on July…
-
3 months ago benzinga.com
Wells Fargo Initiates Coverage On X4 Pharmaceuticals with Overweight Rating, Announces Price Target of $11
Wells Fargo analyst Derek Archila initiates coverage on X4 Pharmaceuticals (NASDAQ:XFOR) with a Overweight rating and announces Price Target of $11.
3 months ago globenewswire.com
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, July 07, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that, effective on July…
4 months ago globenewswire.com
X4 Pharmaceuticals Appoints Kelly Gold, Experienced Chief Financial Officer, to its Board of Directors
BOSTON, July 01, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced the appointment of Kelly…
-
5 months ago benzinga.com
Leerink Partners Initiates Coverage On X4 Pharmaceuticals with Outperform Rating, Announces Price Target of $12
Leerink Partners analyst Thomas Smith initiates coverage on X4 Pharmaceuticals (NASDAQ:XFOR) with a Outperform rating and announces Price Target of $12.
5 months ago globenewswire.com
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, June 01, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that, effective on May…
-
5 months ago benzinga.com
X4 Pharmaceuticals Q1 EPS $(0.16) Beats $(0.20) Estimate, Sales $2.708M Miss $3.200M Estimate
X4 Pharmaceuticals (NASDAQ:XFOR) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.20) by 20 percent. This is a 500 percent decrease over earnings of…
-
6 months ago benzinga.com
X4 Pharma Says EC Grants Marketing Authorization For XOLREMDI Capsules For Treatment Of Patients With WHIM Syndrome In EU
- European Commercialization will be Led by X4 Pharmaceuticals' Partner, Norgine - - Global, Pivotal Phase 3 Clinical Trial Ongoing to Evaluate Mavorixafor in Chronic Neutropenia -BOSTON, April 29,…
7 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
7 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
-
7 months ago benzinga.com
X4 Pharmaceuticals Q4 EPS $(0.22) Beats $(0.38) Estimate, Sales $2.568M Beat $1.733M Estimate
X4 Pharmaceuticals (NASDAQ:XFOR) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.38) by 42.11 percent. This is a 96.26 percent increase over losses of…
-
7 months ago benzinga.com
Guggenheim Initiates Coverage On X4 Pharmaceuticals with Buy Rating, Announces Price Target of $12
Guggenheim analyst Michael Schmidt initiates coverage on X4 Pharmaceuticals (NASDAQ:XFOR) with a Buy rating and announces Price Target of $12.
-
8 months ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
10 months ago benzinga.com
Dynavax Technologies, Omeros, Agios Pharmaceuticals, Nike And Other Big Stocks Moving Higher On Wednesday
Dynavax Technologies, Omeros, Agios Pharmaceuticals, Nike And Other Big Stocks Moving Higher On Wednesday
-
11 months ago benzinga.com
Stifel Maintains Buy on X4 Pharmaceuticals, Raises Price Target to $10
Stifel analyst James Condulis maintains X4 Pharmaceuticals (NASDAQ:XFOR) with a Buy and raises the price target from $7.5 to $10.
-
11 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on X4 Pharmaceuticals, Raises Price Target to $5
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains X4 Pharmaceuticals (NASDAQ:XFOR) with a Buy and raises the price target from $3.5 to $5.
-
12 months ago benzinga.com
X4 Pharmaceuticals Q3 EPS $(0.69) Beats $(0.82) Estimate, Sales $1.765M Miss $1.901M Estimate
X4 Pharmaceuticals (NASDAQ:XFOR) reported quarterly losses of $(0.69) per share which beat the analyst consensus estimate of $(0.82) by 15.85 percent. This is a 87.41 percent increase over losses of…
-
1 year ago benzinga.com
X4 Pharmaceuticals Prices $135M Public Offering Of 45.86M Common Shares At $2.90 Each To Advance Phase 3 Rare Disease Program
And, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 700,000 shares of its common stock at a public offering price of $2.899 per pre-funded warrant. The pre-funded…
-
1 year ago benzinga.com
X4 Pharmaceuticals Launches Of An Underwritten Public Offering Of Its Common Stock; No Financial Terms Disclosed
X4 Pharmaceuticals (NASDAQ:XFOR) ("X4" or the "Company"), a company driven to improve the lives of people with rare hematology diseases, today announced that it has commenced an underwritten public…
-
1 year ago benzinga.com
X4 Pharmaceuticals Announces Strategic Restructuring With 50% Workforce Reduction Expected To Deliver $13M Annualized Cost Savings
Organizational restructuring including a 50% reduction in workforce that is anticipated to result in annualized cost savings of approximately $13MJohn Volpone appointed Chief Operating Officer, in…
-
1 year ago benzinga.com
Stifel Maintains Buy on X4 Pharmaceuticals, Lowers Price Target to $9
Stifel analyst Stephen Willey maintains X4 Pharmaceuticals (NASDAQ:XFOR) with a Buy and lowers the price target from $30 to $9.
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
12 Health Care Stocks Moving In Monday's After-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
-
1 year ago benzinga.com
HC Wainwright & Co. Maintains Buy on X4 Pharmaceuticals, Lowers Price Target to $3.5
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains X4 Pharmaceuticals (NASDAQ:XFOR) with a Buy and lowers the price target from $7 to $3.5.
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
-
1 year ago benzinga.com
X4 Pharmaceuticals Announced Private Placement In Public Equity Financing Of Approximately $60M
$60 million PIPE financing led by Coastlands Capital, Bain Capital Life Sciences and New Enterprise AssociatesNewly appointed board and management team includes Dr. Adam Craig as Executive Chairman,…
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Monday's Intraday Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Thursday's After-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
12 Health Care Stocks Moving In Thursday's Intraday Session